Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Protagonist Therapeutics’ (PTGX) filings—rich with peptide-science jargon, cash-runway disclosures, and collaboration milestones—can be overwhelming. Whether you’re scanning a sudden 8-K or tracing capital raises, the information you need hides in technical detail. That’s why investors search for “understanding Protagonist Therapeutics SEC documents with AI” and “Protagonist Therapeutics SEC filings explained simply.”
Stock Titan turns that challenge into clarity. Our platform delivers AI-powered summaries that highlight trial updates, partnership economics, and risk factors inside every Protagonist Therapeutics annual report 10-K simplified, each Protagonist Therapeutics quarterly earnings report 10-Q filing, and even the briefest Protagonist Therapeutics 8-K material events explained. Real-time alerts flag Protagonist Therapeutics Form 4 insider transactions real-time, so you never miss new Protagonist Therapeutics executive stock transactions Form 4. Need detail? Click into a filing and our expert notes walk you straight to cash-position tables, IL-23 program costs, or board-level pay disclosures from the Protagonist Therapeutics proxy statement executive compensation section.
Use these insights to act faster: compare revenue from milestone payments with R&D burn in our Protagonist Therapeutics earnings report filing analysis; monitor Protagonist Therapeutics insider trading Form 4 transactions ahead of data readouts; or archive every disclosure for audits. With comprehensive coverage of all forms—10-K, 10-Q, 8-K, S-3, Schedule 13G—and continuous EDGAR updates, Stock Titan equips you to follow this clinical-stage biotech’s journey from lab bench to commercial launch, without wading through hundreds of pages on your own.
Protagonist Therapeutics, Inc. (PTGX) reported an insider equity change involving its President and CEO, who is also a director. On 11/21/2025, the reporting person made a bona fide gift of 440 shares of common stock, identified with transaction code "G" for a gift. The filing notes that the gift was made to the reporting person’s grandchild.
Following this gift transaction, the reporting person beneficially owns 519,543 shares of PTGX common stock, held directly. This Form 4 reflects a personal, non-sale transfer and does not describe any purchase or sale of shares on the market.
Protagonist Therapeutics, Inc. (PTGX) reported an insider tax-related sale by its Chief Medical Officer. On 11/17/2025, Chief Medical Officer Arturo Molina reported selling 2,712 shares of common stock at a price of $84.77 per share. The sale was made to cover tax withholding obligations incurred when restricted stock units settled, rather than as an open-market discretionary sale.
Following this transaction, Arturo Molina beneficially owned 81,180 shares of Protagonist Therapeutics common stock in direct form. The filing was made by a single reporting person and does not list any derivative securities transactions.
Protagonist Therapeutics (PTGX) filed its Q3 2025 10‑Q, highlighting steady collaboration revenue and strong liquidity. License and collaboration revenue was $4.7 million for the quarter and $38.6 million year-to-date, primarily from the Takeda rusfertide agreement. The company reported a net loss of $39.3 million for Q3 and $85.8 million for the first nine months, reflecting ongoing Phase 3 development and operating costs.
Cash, cash equivalents, and marketable securities totaled $678.8 million as of September 30, 2025, supported by prior upfronts and a $25.0 million milestone from Takeda received in September 2025. Deferred revenue was $17.0 million, to be recognized as development services conclude. R&D expense was $40.0 million and G&A was $11.1 million in Q3.
Operationally, JNJ submitted an NDA to the FDA in July 2025 and an MAA to the EMA in September 2025 for icotrokinra in plaque psoriasis. Rusfertide for polycythemia vera received FDA Breakthrough Therapy designation in August 2025, with Phase 3 VERIFY positive topline results announced in March 2025. As of October 29, 2025, 62,515,666 common shares were outstanding.
Protagonist Therapeutics (PTGX) filed a current report announcing it has reported financial results for the quarter ended September 30, 2025. The company furnished a press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” as Exhibit 99.1.
The report states the information, including the exhibit, is furnished and not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings. The filing lists PTGX common stock on The Nasdaq Stock Market and is signed by Chief Financial Officer Asif Ali.
Protagonist Therapeutics (PTGX)
Sales included 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average, with individual trades ranging from $86.71 to $88.00. Following these transactions, he directly holds 5,130 shares. The exercised options were fully vested and were set to expire on 05/28/2028.
Protagonist Therapeutics, Inc. (PTGX) reported an insider notice to sell 12,000 common shares via Morgan Stanley Smith Barney on
Two prior 10b5-1 sales attributed to William Waddill are disclosed:
Protagonist Therapeutics director William D. Waddill sold 4,000 shares of Protagonist Therapeutics, Inc. (PTGX) common stock on 09/22/2025 at a price of $64.25 per share, leaving him with 5,130 shares beneficially owned following the transaction. The sale was executed under a Rule 10b5-1 trading plan that the reporting person adopted on November 10, 2023. The Form 4 was signed on behalf of Mr. Waddill by an attorney-in-fact on 09/24/2025. The filing reports the transaction as a non-derivative disposition by a director and indicates the Form was filed by one reporting person.
Form 144 notice for Protagonist Therapeutics, Inc. (PTGX) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $248,800 and an approximate sale date of 09/22/2025 on NASDAQ. The filer acquired the shares on 05/03/2022 via previously exercised stock options and paid cash. The filing also discloses a 10b5-1 sale by the same person of 4,000 shares on 08/27/2025 for gross proceeds of $237,000. The notice includes the seller’s representation about absence of undisclosed material adverse information.
Dinesh V. Patel, Ph.D., President and CEO and director of Protagonist Therapeutics, Inc. (PTGX), reported a change in beneficial ownership on Form 4. The filing discloses a transaction dated 09/16/2025 in which Dr. Patel made a bona fide gift of 620 shares of the issuer's common stock to his son at a reported price of $0 (coded G). After the reported transaction, Dr. Patel beneficially owned 519,983 shares, held directly. The Form 4 was signed on 09/18/2025 by Matthew Gosling as attorney-in-fact for Dr. Patel.
William D. Waddill, a director of Protagonist Therapeutics, Inc. (PTGX), sold 4,000 shares of common stock on 08/27/2025 at $59.25 per share under a Rule 10b5-1 trading plan adopted on November 10, 2023. After the sale he beneficially owns 9,130 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/29/2025, and the filing indicates the transaction was effected pursuant to the pre-established 10b5-1 plan.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
